Phio Pharmaceuticals Corp.

Company to Highlight Next Stage of PH-762 Clinical Development in Cutaneous Squamous Cell Carcinoma King of Prussia, Pennsylvania–(Newsfile Corp. – September 23, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biopharmaceutical company developing therapeutics using its proprietary INTASYL® siRNA gene silencing technology to eliminate cancer, today announced that it will present at the Life […] The post Phio Pharmaceuticals to Present Clinical Development Update and Upcoming Catalysts at Life Sciences Future 2026 Conference appeared first on Phio Pharmaceuticals.

Company Proposes Planned Phase 2b Neoadjuvant Study Following Successful Completion of Phase 1b Trial King of Prussia, Pennsylvania–(Newsfile Corp. – September 14, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that, following the formal completion […] The post Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma appeared first on Phio Pharmaceuticals.

Management to Meet with Investors and Highlight Progress and Future Development Plans for PH-762 King of Prussia, Pennsylvania–(Newsfile Corp. – September 11, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing therapeutics based on its proprietary INTASYL® siRNA gene-silencing technology designed to eliminate cancer, today announced that members of its management team […] The post Phio Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference appeared first on Phio Pharmaceuticals.

PH-894 protection for chemical structure, genetic sequencing and broad application for proliferative and infectious diseases in U.S. King of Prussia, Pennsylvania–(Newsfile Corp. – August 11, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing immuno-oncology therapeutics based on its proprietary INTASYL® gene-silencing technology, today announced the receipt of a U.S. Notice of […] The post Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894 appeared first on Phio Pharmaceuticals.

Strategic milestone advancements for lead clinical candidate PH-762 Initiation of commercial scale API, long term non-clinical toxicology, completion of Phase 1b pharmacology, and new IP announcements King of Prussia, Pennsylvania–(Newsfile Corp. – August 6, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing […] The post Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update appeared first on Phio Pharmaceuticals.

Live Presentation and Q&A: Tuesday, July 28, 2026 12 PM EDT King of Prussia, Pennsylvania–(Newsfile Corp. – July 22, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of […] The post Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series appeared first on Phio Pharmaceuticals.

Live Presentation and Q&A: Thursday, July 28, 2026 12 PM EDT King of Prussia, Pennsylvania–(Newsfile Corp. – July 22, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of […] The post Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series appeared first on Phio Pharmaceuticals.

Brings extensive experience in patient care, dermatologic research and commercialization King of Prussia, Pennsylvania–(Newsfile Corp. – July 21, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio is pleased to announce that R. Todd Plott, M.D. has been […] The post Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors appeared first on Phio Pharmaceuticals.

Securing additional patent protection in the United States, Canada, and Japan for INTASYL Compounds King of Prussia, Pennsylvania–(Newsfile Corp. – July 15, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today significant progress in the […] The post Phio Pharmaceuticals Announces Patent Milestone with Multiple Notices of Allowance and Grant Decision appeared first on Phio Pharmaceuticals.

Live Presentation and Q&A: Tuesday, June 30, 2026 12 PM EDT King of Prussia, Pennsylvania–(Newsfile Corp. – June 26, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of […] The post Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series appeared first on Phio Pharmaceuticals.